Category Archives: Myocardial Infarction

Share this Article You are free to share this article under the Attribution 4.0 International license. Even a few hours of exposure to ambient ultrafine particles common in air pollution may potentially trigger nonfatal heart attacks, research suggests Continue reading →

Recardio announces conclusion of interim analysis of Phase 2 in AMI Treatment trials across various pharmaceutical companies are on the go lately. Supporting the same, Recardio, one of the clinical stage life science companies, reportedly announced the completion of an interim analysis of its Phase 2 study of dutogliptin and filgrastim, combined, in early recovery post-myocardial infarction. Moreover, it has been estimated that the patient recruitment for the study is still continuing at all the participating centers of the company. Continue reading →

Are you living in an area where the air pollution level is too much? If yes, you may be at an increased risk of developing myocardial infarction which is also called a heart attack. A recent study published in the journal Environmental Health Perspectives has revealed that exposure to an elevated level of ultrafine particles (particles that are 100 nanometers or smaller in size) can make you susceptible to a heart attack. Continue reading →

Migraine headache, particularly migraine with aura, is associated with increased risk for cardiovascular disease and cerebrovascular events, including ischemic stroke. In light of the high prevalence of migraine headache, this association should be further investigated, according to a review published in the Journal of the American Heart Association. Other than the characteristic headache, migraine may be associated with transient focal neurology symptoms (eg, aura) that usually persist for less than an hour Continue reading →

This press release was orginally distributed by SBWire Albany, NY -- (SBWIRE) -- 02/19/2020 -- Tissue Plasminogen Activator: Introduction Tissue plasminogen activator (tPA) is an enzyme associated with breakdown of blood clots (fibrinolysis). It is a serine protease present in endothelial cells. Conversion of plasminogen to plasmin is catalyzed with the help of serine protease. Continue reading →

New Amgen Survey Shows Heart Attack Survivors in Canada Do Not Know Their Cholesterol Level or What It Should Be MISSISSAUGA, ON , Feb. 6, 2020 /CNW/ - In recognition of February as Heart Month, Amgen Canada ("Amgen") today released Canadian findings as part of a global survey1 that evaluated worldwide heart attack survivors' perceptions and awareness of the connection between cholesterol and cardiovascular (CV) events revealing that 56 per cent of respondents in Canada do not consider high cholesterol to be a chronic condition requiring long-term management and care.2 Amgen (CNW Group/Amgen Canada) Low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, is one of the most important modifiable risk factors for heart attack.3 Globally more than 40% of patients who have had a CV event, like a heart attack, will go on to have another within two years.4 The survey's findings show that while heart attack survivors are proactively trying to improve their cardiovascular health, they may not fully understand the importance of lowering high LDL-C to reduce their risk of another heart attack: "Cardiovascular disease remains one of the most significant health challenges in Canada where an estimated 63,200 adults will experience a first heart attack this year7," said Ponda Motsepe-Ditshego, Executive Medical Director at Amgen Canada."This survey shows patients want to reduce their risk of another heart attack, but are unsure about the best actions to take. Continue reading →

The optimal dose of beta blockers after acutemyocardial infarction(MI) remains uncertain. We evaluated the effectiveness of low-dose nebivolol, a beta1 blocker and a vasodilator, in patients with acute MI. A total of 625 patients with acute MI from 14 teaching hospitals in Korea were divided into 2 groups according to the dose of nebivolol (nebistol, Elyson Pharmaceutical Co., Ltd., Seoul, Korea): low-dose group (1.25 mg daily, n=219) and usual- to high-dose group (2.5 mg daily, n=406) Continue reading →

A leading research firm, Zion Market Research added a latest industry report on Myocardial Infarction Treatment Market consisting of 110+ pages during the forecast period and Myocardial Infarction Treatment Market report offers a comprehensive research updates and information related to market growth, demand, opportunities in the global Myocardial Infarction Treatment Market. According to the report the Global Myocardial Infarction Treatment Market Set to reach USD 1726.3 Million by end of 2022 The following report contains an interpretation of the marketing plan for Myocardial Infarction Treatment Market. This Myocardial Infarction Treatment Market report offers the clients with a unique opportunity that can drive them to higher levels of success and to great achievement. Continue reading →

The performance of the European Society of Cardiology (ESC) algorithm, ESC 0/1-h, in ruling out acute myocardial infarction (AMI) without ST-elevation was comparable in patients with and without diabetes mellitus (DM), according to a study published in Diabetes Care. The ESC 0/1-h and 0/3-h algorithms are used to diagnose patients with suspected acute non-ST-elevation myocardial infarction (NSTEMI) Continue reading →

OBJECTIVE: Acutemyocardial infarction(AMI) carries increased risk of mortality and excess costs. Disease Management Programs (DMPs) providing guideline-recommended care for chronic diseases seem an intuitively appealing way to enhance health outcomes for patients with chronic conditions such as AMI Continue reading →